Pediatrics & Child Health Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM

This Phase 3 trial is focused on children recovering from complicated severe acute malnutrition (SAM) in Kenya, Zambia, and Zimbabwe. It tests new antimicrobial and behavioral treatments designed to improve survival and recovery after hospital discharge by tackling infections and social challenges. For families dealing with SAM, this study represents hope for better health outcomes and support during a critical recovery period.

Trial of an AI-enabled Digital Stethoscope to Improve Antibiotic Stewardship

Researchers in Bangladesh are testing an AI-powered digital stethoscope to help doctors more accurately diagnose respiratory infections in children. By improving diagnosis, the trial aims to reduce unnecessary antibiotic use, which is important for preventing antibiotic resistance and protecting children’s health. This technology could make a big difference in how respiratory illnesses are treated, especially in areas with limited healthcare resources.

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

This Phase 3 trial is exploring a new medication called Orforglipron for children and teens with obesity or overweight, recruiting participants across several countries including the United States and Brazil. If the medication proves safe and effective, it might offer a new option to help manage weight in young people, which is important for their long-term health and well-being. Families affected by childhood obesity may find new hope in this research.

Safety of RSV Preventive Monoclonal Antibody

This study in the United States is looking at whether a preventive antibody for respiratory syncytial virus (RSV) can be safely given at the same time as routine childhood vaccines. Combining these treatments could mean fewer clinic visits for infants and families, making it easier to protect children against RSV and other illnesses at once. This could simplify immunization schedules and reduce stress for caregivers.

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

This Phase 3 trial tested a drug called GM-CSF for children with sepsis-induced multiple organ dysfunction syndrome who experience immune system paralysis. Completed across 25 U.S. sites, the study aims to see if this drug can help restore immune function and improve recovery in critically ill children. Results are pending, but this research could lead to better treatments for children facing severe infections and organ failure.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.